AstraZeneca and MedImmune

Our major focus is to develop medicines for Oncology, Respiratory, Inflammation and Autoimmunity, and Cardiovascular and Metabolic diseases, with an opportunity-driven approach to Infection, Neuroscience and Gastrointestinal diseases.

Our two R&D biotech units, MedImmune and IMED, use novel science and innovation in biologics, small molecules, immunotherapies, protein engineering and devices, to provide candidate medicines for our late-stage development unit.

By co-locating our R&D next to world leading bioscience clusters in Cambridge, UK; Gaithersburg, Maryland, US; and Gothenburg, Sweden, we can collaborate with leading scientists and research organisations.

We have extensive research collaborations with our neighbours on the Campus including with the hospital and University departments and partner institutions.